Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis (AMSC-ALS-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03828123
Recruitment Status : Completed
First Posted : February 4, 2019
Last Update Posted : February 12, 2019
Sponsor:
Collaborator:
Department of Neurology, University Hospital Motol, Prague, Czech Republic
Information provided by (Responsible Party):
Bioinova, s.r.o.

Brief Summary:
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that targets motor neurons. Prognosis is invariably fatal within 3-5 years since manifestation of the disease. Despite improved understanding of the mechanisms underlying ALS, the treatment remains essentially only supportive and focused on symptoms relief. Over the past few years, stem cell research has expanded greatly as a tool for developing new therapies to treat incurable diseases. Stem cell therapy has been shown as promising in several animal ALS models and human clinical trials.

Condition or disease Intervention/treatment Phase
Motor Neuron Disease, Amyotrophic Lateral Sclerosis Biological: Suspension of human autologous MSC 3P in 1.5 ml Phase 1 Phase 2

Detailed Description:
Subjects will be assigned to autologous mesenchymal stromal cell (AMSC) treatment according to inclusion and exclusion criteria (see below) screened four times prior to administration. Then the subjects will be observed for three consecutive yearsAfter a half year of screening period, the autologous multipotent mesenchymal stromal cells from bone marrow will be isolated. The cells will be cultivated for 3 passages (3 - 4 weeks) in order to get sufficient amount for therapy, cell suspension for intrathecal application will be prepared and introduced intrathecally through lumbar puncture. Subsequently, all the subjects will be observed at the range of standard medical care used at these types of interventions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Non-randomized, Open Label Study to Assess the Safety and the Efficacy of Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis
Actual Study Start Date : January 2012
Actual Primary Completion Date : August 18, 2017
Actual Study Completion Date : August 18, 2017


Arm Intervention/treatment
Experimental: Autologous Multipotent MSC
Patients with intrathecal administration of Suspension of human autologous MSC 3P in 1.5 ml
Biological: Suspension of human autologous MSC 3P in 1.5 ml
Intrathecal application of Autologous Multipotent Mesenchymal Stromal Cells 3P suspension




Primary Outcome Measures :
  1. Safety: Complications related to the medicinal product application - new neurological deficit and occurrence of other adverse events [ Time Frame: 1 year ]

    Complications at the site of intrathecal infusion of the medicinal product and no new neurological deficit (meningism, paraplegia, urinary incontinence) not attributed to the natural progression of the ALS disease will be recorded at Visits I, III, IV, V, VI, and IX. Occurrence of other potential adverse events, including headache, respiratory failure, leukocytosis, cervical spine stenosis, cystitis and hyperhydrosis will be evaluated on the severity scale (1=mild, 2=moderate, 3=severe).

    Brain and spinal cord MRI will be performed at Visits I and IX to exclude treatment-related tumor formation, pathological contrast enhancement or other structural pathology.



Secondary Outcome Measures :
  1. Efficacy: Inhibition of the disease progression - ALS functional rating scale [ Time Frame: 18 months ]

    Inhibition of the disease progression will be recorded by ALS functional rating scale (ALSFRS) at Visits I, III, and VI through X.

    Measures (all 4-0):

    1. speech
    2. salivation
    3. swallowing
    4. handwriting
    5. cutting food and handling utensils (with or without gastrostomy)
    6. dressing and hygiene
    7. turning in bed and adjusting bed clothes
    8. walking
    9. climbing stairs
    10. breathing

    ALSFRS = SUM (points for all 10 measures)

    Interpretation:

    minimum score: 0 maximum score: 40 The higher the score the more function is retained.


  2. Efficacy: Inhibition of the disease progression - Norris scale [ Time Frame: 18 months ]

    Inhibition of the disease progression will be recorded by Norris scale at Visits I, III, and VI through X.

    Norris scal has has 22 items examining bulbar, respiratory, trunk, arm, leg, and general domains involving reflexes, fasciculation, and muscle atrophy. The scale also measures emotional lability, fatigability and leg rigidity. The Norris scale has a linear decline during the course of ALS.


  3. Efficacy: Inhibition of the disease progression - Forced vital capacity (FVC) [ Time Frame: 18 months ]
    FVC (%) will be measured at Visits I, and VI through X.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. established diagnosis of definite ALS according to El Escorial criteria
  2. riluzole naive or stable dose for at least 2 months,
  3. life expectancy more than 2 years
  4. patients able to provide written informed consent.

Exclusion Criteria:

  1. FVC less than 70%
  2. in case of primary bulbar paralysis less than 15 points on Norris bulbar scale,
  3. less than 15 points on Norris spinal scale,
  4. pregnancy, breastfeeding
  5. coagulopathy,
  6. skin infection at the site of bone marrow aspiration or application of the cell product,
  7. gastrostomy,
  8. any significant medical condition that would compromise the safety of the patient (e.g. recent myocardial infarction, congestive heart failure, renal failure, liver failure, cancer, systemic infection, recurrent thromboembolic disease .....),
  9. alcohol or drug abuse
  10. cancer.
  11. women of childbearing potential not using effective contraception (established oral contraception, intrauterine device, ligation of the uterine tube) including proven contraceptive measures taken by their sexual partners
  12. fertile men not using proven contraceptive measures including effective contraception of their partner (established oral contraception, intrauterine device, ligation of the uterine tube)

Publications of Results:
Layout table for additonal information
Responsible Party: Bioinova, s.r.o.
ClinicalTrials.gov Identifier: NCT03828123     History of Changes
Other Study ID Numbers: AMSC-ALS-001
First Posted: February 4, 2019    Key Record Dates
Last Update Posted: February 12, 2019
Last Verified: February 2019

Additional relevant MeSH terms:
Layout table for MeSH terms
Sclerosis
Amyotrophic Lateral Sclerosis
Pathologic Processes
Motor Neuron Disease
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases